We are proud to announce that the Novo Nordisk Foundation BioInnovation Institute (BII) has decided to invest DKK 10m ($1.5m) in Synklino. As a part of BII’s Creation House Programme we will have an ideal opportunity to accelerate our technical and commercial validation, to strengthen the company’s core competences, and attract additional funding that can bring our drug candidate further in pre-clinical development